UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☑ | QUARTERLY Report PURSUANT TO Section 13 or 15( | |
For the quarterly period ended | ||
or
☐ | Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | |
For the transition period from __________ to ____________ |
Commission File No. 001-33407
ISORAY, INC.
(Exact name of registrant as specified in its charter)
Minnesota | 41-1458152 |
(State or other jurisdiction of incorporation or | (I.R.S. Employer |
|
|
350 Hills St., Suite 106, Richland, Washington | 99354 |
(Address of principal executive offices) | (Zip Code) |
|
|
Registrant's telephone number, including area code: (509) 375-1202 |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ |
| Accelerated filer | ☐ |
Non-accelerated filer | ☐ |
| ||
| Smaller reporting company | ☒ | ||
|
|
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionSection 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒
Number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date:
Class | Outstanding as of |
Common stock, $0.001 par value |
|
Table of Contents
PART I |
| |
|
|
|
Item 1 | 1 | |
|
|
|
| 1 | |
|
|
|
| 2 | |
|
|
|
| 3 | |
|
|
|
| 4 | |
|
|
|
Item 2 |
| 11 |
|
|
|
Item 3 |
| |
|
|
|
Item 4 |
| |
|
|
|
PART II |
| |
|
|
|
Item 1 |
| |
|
|
|
Item 1A |
| |
|
|
|
Item 2 |
| |
|
|
|
Item 3 |
| |
|
|
|
Item 4 |
| |
|
|
|
Item 5 |
| |
|
|
|
Item 6 |
| |
|
|
|
|
|
PART I – FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
IsoRay, Inc. and Subsidiaries |
Consolidated Balance Sheets (Unaudited) |
(In thousands, except shares) |
December 31, | June 30, | September 30, | June 30, | |||||||||||||
2017 | 2017 | 2018 | 2018 | |||||||||||||
| (unaudited) | |||||||||||||||
ASSETS | ||||||||||||||||
ASSET | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash and cash equivalents | $ | 2,951 | $ | 5,932 | $ | 2,193 | $ | 2,600 | ||||||||
Certificates of deposit (Note 3) | 2,725 | 3,039 | ||||||||||||||
Short-term investments (Note 3) | 7,000 | 825 | ||||||||||||||
Accounts receivable, net of allowance for doubtful accounts of $26 and $26, respectively | 987 | 726 | 1,071 | 1,192 | ||||||||||||
Inventory | 459 | 323 | 487 | 494 | ||||||||||||
Prepaid expenses and other current assets | 295 | 271 | 517 | 335 | ||||||||||||
Total current assets | 7,417 | 10,291 | 11,268 | 5,446 | ||||||||||||
Property and equipment, net | 1,168 | 1,054 | 1,394 | 1,311 | ||||||||||||
Restricted cash | 181 | 181 | 181 | 181 | ||||||||||||
Inventory, non-current | 408 | 513 | 316 | 319 | ||||||||||||
Other assets, net of accumulated amortization | 204 | 230 | 185 | 198 | ||||||||||||
Total assets | $ | 9,378 | $ | 12,269 | $ | 13,344 | $ | 7,455 | ||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Accounts payable and accrued expenses | $ | 581 | $ | 630 | $ | 1,167 | $ | 1,391 | ||||||||
Accrued protocol expense | 43 | 75 | 125 | 77 | ||||||||||||
Accrued radioactive waste disposal | 19 | 125 | 45 | 37 | ||||||||||||
Accrued payroll and related taxes | 165 | 138 | 125 | �� | 155 | |||||||||||
Accrued vacation | 123 | 138 | 175 | 175 | ||||||||||||
Total current liabilities | 931 | 1,106 | 1,637 | 1,835 | ||||||||||||
Long-term liabilities: | ||||||||||||||||
Asset retirement obligation | 576 | 561 | 598 | 590 | ||||||||||||
Total liabilities | 1,507 | 1,667 | 2,235 | 2,425 | ||||||||||||
Commitments and contingencies (Note 8) | ||||||||||||||||
Shareholders' equity: | ||||||||||||||||
Preferred stock, $.001 par value; 7,001,671 shares authorized: | ||||||||||||||||
Series A: 1,000,000 shares allocated; no shares issued and outstanding | - | - | - | - | ||||||||||||
Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding | - | - | - | - | ||||||||||||
Series C: 1,000,000 shares allocated; no shares issued and outstanding | - | - | - | - | ||||||||||||
Series D: 1,671 shares allocated; no shares issued and outstanding | - | - | - | - | ||||||||||||
Common stock, $.001 par value; 192,998,329 shares authorized; 55,100,229 and 55,017,419 shares issued and outstanding | 55 | 55 | ||||||||||||||
Common stock, $.001 par value; 192,998,329 shares authorized; 67,331,147 and 56,331,147 shares issued and outstanding | 67 | 56 | ||||||||||||||
Additional paid-in capital | 83,430 | 83,151 | 91,898 | 84,322 | ||||||||||||
Accumulated deficit | (75,614 | ) | (72,604 | ) | (80,856 | ) | (79,348 | ) | ||||||||
Total shareholders' equity | 7,871 | 10,602 | 11,109 | 5,030 | ||||||||||||
Total liabilities and shareholders' equity | $ | 9,378 | $ | 12,269 | �� | $ | 13,344 | $ | 7,455 |
The accompanying notes are an integral part of these consolidated financial statements. |
Consolidated Statements of Operations (Unaudited) |
(Dollars and shares in thousands, except for per-share amounts) |
Three months ended | Six months ended | |||||||||||||||||||||||
December 31, | December 31, | Quarter ended September 30, | ||||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | 2018 | 2017 | |||||||||||||||||||
Product sales, net | $ | 1,536 | $ | 1,028 | $ | 2,747 | $ | 2,109 | $ | 1,562 | $ | 1,211 | ||||||||||||
Cost of product sales | 1,005 | 1,029 | 1,951 | 2,062 | 1,038 | 946 | ||||||||||||||||||
Gross profit / (loss) | 531 | (1 | ) | 796 | 47 | |||||||||||||||||||
Gross profit | 524 | 265 | ||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||
Research and development | ||||||||||||||||||||||||
Proprietary research and development | 311 | 150 | 597 | 322 | ||||||||||||||||||||
Collaboration arrangement, net of reimbursement (Note 8) | 29 | - | 104 | - | ||||||||||||||||||||
Propriety research and development | 394 | 287 | ||||||||||||||||||||||
Collaboration arrangement, net of reimbursement | 26 | 75 | ||||||||||||||||||||||
Total research and development | 340 | 150 | 701 | 322 | 420 | 362 | ||||||||||||||||||
Sales and marketing | 674 | 496 | 1,288 | 1,020 | 649 | 614 | ||||||||||||||||||
General and administrative | 985 | 880 | 1,827 | 1,807 | 973 | 841 | ||||||||||||||||||
Change in estimate of asset retirement obligation | - | (48 | ) | - | (48 | ) | ||||||||||||||||||
Total operating expenses | 1,999 | 1,478 | 3,816 | 3,101 | 2,042 | 1,817 | ||||||||||||||||||
Operating loss | (1,468 | ) | (1,479 | ) | (3,020 | ) | (3,054 | ) | (1,518 | ) | (1,552 | ) | ||||||||||||
Non-operating income: | ||||||||||||||||||||||||
Interest income, net | 5 | 29 | 10 | 60 | 10 | 6 | ||||||||||||||||||
Change in fair value of warrant derivative liability | - | - | - | 27 | ||||||||||||||||||||
Other income | - | - | - | 20 | ||||||||||||||||||||
Non-operating income, net | 5 | 29 | 10 | 107 | 10 | 6 | ||||||||||||||||||
Net loss | (1,463 | ) | (1,450 | ) | (3,010 | ) | (2,947 | ) | (1,508 | ) | (1,546 | ) | ||||||||||||
Preferred stock dividends | (3 | ) | (2 | ) | (5 | ) | (5 | ) | (3 | ) | (3 | ) | ||||||||||||
Net loss applicable to common shareholders | $ | (1,466 | ) | $ | (1,452 | ) | $ | (3,015 | ) | $ | (2,952 | ) | (1,511 | ) | (1,549 | ) | ||||||||
Basic and diluted loss per share | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.02 | ) | $ | (0.03 | ) | ||||||
Weighted average shares used in computing net loss per share: | ||||||||||||||||||||||||
Basic and diluted | 55,056 | 55,017 | 55,037 | 55,014 | 66,147 | 55,017 |
The accompanying notes are an integral part of these consolidated financial statements. |
Consolidated Statements of Cash Flows (Unaudited) |
(In thousands) |
Six months ended December 31, | Quarter ended September 30, | |||||||||||||||
2017 | 2016 | 2018 | 2017 | |||||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||||||
Net loss | $ | (3,010 | ) | $ | (2,947 | ) | $ | (1,508 | ) | $ | (1,546 | ) | ||||
Adjustments to reconcile net loss to net cash used by operating activities: | ||||||||||||||||
Depreciation expense | 36 | 32 | 32 | 18 | ||||||||||||
Loss on equipment disposals | - | 5 | ||||||||||||||
Amortization of other assets | 26 | 23 | 12 | 13 | ||||||||||||
Change in fair value of warrant derivative liability | - | (27 | ) | |||||||||||||
Accretion of asset retirement obligation | 15 | 15 | 8 | 7 | ||||||||||||
Change in estimate of asset retirement obligation | - | (48 | ) | |||||||||||||
Share-based compensation | 240 | 122 | 93 | 90 | ||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts receivable, gross | (261 | ) | (22 | ) | 121 | (17 | ) | |||||||||
Inventory | (31 | ) | (24 | ) | 10 | (44 | ) | |||||||||
Prepaid expenses and other current assets | (24 | ) | 79 | (182 | ) | (143 | ) | |||||||||
Accounts payable and accrued expenses | (49 | ) | (299 | ) | (224 | ) | 181 | |||||||||
Accrued protocol expense | (32 | ) | 34 | 48 | (10 | ) | ||||||||||
Accrued radioactive waste disposal | (106 | ) | 18 | 9 | (114 | ) | ||||||||||
Accrued payroll and related taxes | 27 | 18 | (30 | ) | (104 | ) | ||||||||||
Accrued vacation | (15 | ) | 7 | (1 | ) | 8 | ||||||||||
Net cash used by operating activities | (3,184 | ) | (3,014 | ) | (1,612 | ) | (1,661 | ) | ||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||||||
Additions to property and equipment | (150 | ) | (239 | ) | (114 | ) | (54 | ) | ||||||||
Additions to other assets | - | (151 | ) | |||||||||||||
Proceeds from maturity of certificates of deposit | 3,868 | - | 575 | 3,043 | ||||||||||||
Purchases of and interest from certificates of deposit | (3,554 | ) | (58 | ) | ||||||||||||
Purchases of and interest from certificates of deposit and U.S. Treasury Securities | (6,750 | ) | (3,304 | ) | ||||||||||||
Net cash provided (used) by investing activities | 164 | (448 | ) | |||||||||||||
Net cash used by investing activities | (6,289 | ) | (315 | ) | ||||||||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||||||
Preferred dividends paid | (11 | ) | (11 | ) | ||||||||||||
Proceeds from sales of common stock, pursuant to exercise of options | 50 | 2 | ||||||||||||||
Net cash provided (used) by financing activities | 39 | (9 | ) | |||||||||||||
Proceeds from sales of common stock and warrants, pursuant to registered direct offering, net | 7,494 | - | ||||||||||||||
Net decrease in cash and cash equivalents | (2,981 | ) | (3,471 | ) | ||||||||||||
Cash and cash equivalents, beginning of period | 5,932 | 10,139 | ||||||||||||||
CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | 2,951 | $ | 6,668 | ||||||||||||
Net cash provided by financing activities | 7,494 | - | ||||||||||||||
Net decrease in cash, cash equivalents, and restricted cash | (407 | ) | (1,976 | ) | ||||||||||||
Cash, cash equivalents, and restricted cash beginning of quarter | 2,781 | 6,113 | ||||||||||||||
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF QUARTER | $ | 2,374 | $ | 4,137 | ||||||||||||
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets: | ||||||||||||||||
Cash and cash equivalents | $ | 2,193 | $ | 3,956 | ||||||||||||
Restricted cash | 181 | 181 | ||||||||||||||
Total cash, cash equivalents, and restricted cash shown on the consolidated statement of cashflows | $ | 2,374 | $ | 4,137 | ||||||||||||
Non-cash financing activities: | ||||||||||||||||
Warrants issued to placement agent of registered direct offering | $ | 163 | $ | - |
The accompanying notes are an integral part of these consolidated financial statements. |
Notes to the Unaudited Consolidated Financial Statements
For the sixthree months ended December 31September 30, 20172018 and 20162017
1. | Basis of Presentation |
The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries, referred to herein as “IsoRay” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K10-K for the year ended June 30, 2017.2018.
The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading.
Certain prior period amounts have been reclassified to conform to the current period’speriod’s presentation. The results of operations for the periods presented may not be indicative of those which may be expected for a full year. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 20182019 will be 0%.
2. | New Accounting |
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.2014-09 2014-09 Revenue Recognition, replacing guidance currently codified in Subtopic 605-10605-10 Revenue Recognition-Overall with various SEC Staff Accounting Bulletins providing interpretive guidance. The guidance establishes a new five step principle-based framework in an effort to significantly enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The standard will bebecame effective for the Company in the first quarter of its fiscal year 2019, but early adoption is permitted starting in the first quarter of fiscal year 2018.2019. The Company intends to adoptadopted the new standard in the first quarter of fiscal year 2019 and expects to useused the modified retrospective method. The Company has evaluated the impact of the future adoption of ASU 2014-092014-09 did not have a material impact on itsthe consolidated financial statements of the Company and does did not currently expect significant changes in significantly change the timing of revenue recognition compared to the existingprevious methodology.
In July 2015, February 2016, the FASB issued ASU No.2015-11: Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The ASU became effective for the Company on July 1, 2017. This update did not have a material impact on the Company’s consolidated financial statements upon adoption.
In November 2015, the FASB issued an ASU 2015-17 to simplify the balance sheet classification of deferred taxes. This update requires all deferred tax assets and liabilities to be reported as non-current in the consolidated balance sheets. The ASU became effective for the Company on July 1, 2017. This update did not to have a material impact on the Company’s consolidated financial statements upon adoption.
In February 2016, the FASB issued ASU 2016-022016-02 Leases (Subtopic 842)842), which will require lessees to recognize assetsassets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. The ASU will be effective for the Company in the first quarter of fiscal year 2020. We are currently evaluating the impact of the guidance on the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU No.2016-15 2016-15 Statement of Cash Flows (Topic 230)230): ClassificationClassification of Certain Cash Receipts and Cash Payments. The update provides guidance on classification for cash receipts and payments related to eight specific issues. The update is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2016-15 as of July 1, 2018. The adoption of ASU 2016-15 did not have a material effect on the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. ASU 2016-18 is currently evaluatingintended to clarify how entities present restricted cash in the impactstatement of implementing thiscash flows. The guidance requires entities to show the changes in the total of cash and cash equivalents and restricted cash in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash in the statement of cash flows. When cash and cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and is to be applied retrospectively. Early adoption is permitted, including adoption in an interim period. The Company adopted ASU 2016-18 in the first quarter of fiscal 2019. This update resulted in an increase of $181,000 in cash, cash equivalents, and restricted cash at the beginning of the first period presented on the consolidated financial statements.statement of cash flows.
Other accounting standards that have been issued or proposed by FASB that do notnot require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
3. |
|
The Company had short-term investments consisting of U.S. Treasury Securities and Certificate of Deposit Account Registry Service (CDARS) as of September 30, 2018 and June 30, 2018 respectively.
CDARS is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000$250,000 limit to be fully insured by the Federal Deposit Insurance CorporationCorporation (FDIC). That institution utilizes the CDARS system to purchase certificates of deposit at other financial institutions while keeping the investment at each institution fully insured by the FDIC. CDARS
Short-term investments held by the Company as of December 31, 2017 September 30, 2018 and June 30, 2017 are2018 mature as follows (in thousands):
As of December 31, 2017 | ||||||||||||||||
Under 90 | 91 days to | Six months to | Greater | |||||||||||||
Days | six months | 1 year | than 1 year | |||||||||||||
CDARS | $ | 1,075 | $ | 825 | $ | 825 | $ | - |
As of September 30, 2018 | ||||||||||||||||
Under 90 | 91 days to | Six months to | Greater | |||||||||||||
Days | six months | 1 year | than 1 year | |||||||||||||
U.S. Treasury Securities | $ | 2,333 | $ | 2,333 | $ | 2,334 | $ | - |
As of June 30, 2017 | ||||||||||||||||
Under 90 | 91 days to | Six months to | Greater | |||||||||||||
Days | six months | 1 year | than 1 year | |||||||||||||
CDARS | $ | 3,039 | $ | - | $ | - | $ | - |
As of June 30, 2018 | ||||||||||||||||
Under 90 | 91 days to | Six months to | Greater | |||||||||||||
Days | six months | 1 year | than 1 year | |||||||||||||
CDARS | $ | 825 | $ | - | $ | - | $ | - |
4. | Loss per Share |
Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At December 31,September 30, 2018 and 2017,and 2016, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock, as those would be antidilutive due to the Company’s net loss position.
Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of December 31,September 30, 2018 and 2017,and 2016, were as follows (in thousands):
December 31, | September 30, | |||||||||||||||
2017 | 2016 | 2018 | 2017 | |||||||||||||
Series B preferred stock | 59 | 59 | 59 | 59 | ||||||||||||
Common stock warrants | 250 | 5 | 6,080 | - | ||||||||||||
Common stock options | 3,295 | 2,565 | 3,794 | 3,395 | ||||||||||||
Total potential dilutive securities | 3,604 | 2,629 | 9,933 | 3,454 |
5. | Inventory |
Inventory consisted of the following at December 31, 2017 September 30, 2018 and June 30, 2017 (in2018 (in thousands):
December 31, | June 30, | September 30, | June 30, | |||||||||||||
2017 | 2017 | 2018 | 2018 | |||||||||||||
Raw materials | $ | 367 | $ | 191 | $ | 348 | $ | 371 | ||||||||
Work in process | 82 | 121 | 102 | 96 | ||||||||||||
Finished goods | 10 | 11 | 37 | 27 | ||||||||||||
Total inventory, current | $ | 459 | $ | 323 | $ | 487 | $ | 494 |
December 31, | June 30, | September 30, | June 30, | |||||||||||||
2017 | 2017 | 2018 | 2018 | |||||||||||||
Enriched barium, non-current | $ | 347 | $ | 470 | $ | 272 | $ | 276 | ||||||||
Raw materials, non-current | 61 | 43 | 44 | 43 | ||||||||||||
Total inventory, non-current | $ | 408 | $ | 513 | $ | 316 | $ | 319 |
Inventory, non-current isrepresents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not be consumed within an operating cycle.
cycle and enriched barium. On August 25, 2017, the Company entered into a ConsignmentConsignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-130barium-130 carbonate inventory beginning in November 2017. inventory. The Company anticipates obtaining enough Cesium-131Cesium-131 under this arrangement to obtain over 4,000 curies of Cesium-131 over a ten-year period but thereCesium-131. During the quarter ended September 30, 2018, the Company obtained 230 curies under this agreement which has been used in production. At June 30, 2018, the Company estimated that the remaining enriched barium will result in at least 2,399 curies: 430 of which we believe will be obtained in the year ended June 30, 2019, and 1,969 of which we believe will be obtained after June 30, 2019. There is no assurance as to whether the agreementsagreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the third-party Cesium-131third-party Cesium-131 suppliers will be executed.
6. | Property and Equipment |
Property and equipment consisted of the following at December 31, 2017 September 30, 2018 and June 30, 2017 (in2018 (in thousands):
December 31, | June 30, | September 30, | June 30, | |||||||||||||
2017 | 2017 | 2018 | 2018 | |||||||||||||
Land | $ | 366 | $ | 366 | $ | 366 | $ | 366 | ||||||||
Equipment | 3,799 | 3,776 | 4,153 | 4,152 | ||||||||||||
Leasehold improvements | 4,134 | 4,130 | 4,136 | 4,136 | ||||||||||||
Other1 | 496 | 373 | 437 | 328 | ||||||||||||
Property and equipment | 8,795 | 8,645 | 9,092 | 8,982 | ||||||||||||
Less accumulated depreciation | (7,627 | ) | (7,591 | ) | (7,698 | ) | (7,671 | ) | ||||||||
Property and equipment, net | $ | 1,168 | $ | 1,054 | $ | 1,394 | $ | 1,311 |
1 – Represents1. Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet.sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2017 September 30, 2018 and June 30, 2017 2018 are costs associated with automation of production processes and advance planning and design work on the Company’s new production facility.facility of $207,000.
7. | Share-Based Compensation |
The following table presents the share-based compensation expense recognized for stock-based options during the three months ended December 31,September 30, 2018 and 2017and 2016 (in thousands):
Three Months | ||||||||
2017 | 2016 | |||||||
Cost of product sales | $ | 13 | $ | 17 | ||||
Research and development expenses | 19 | 7 | ||||||
Sales and marketing expenses | 17 | 11 | ||||||
General and administrative expenses | 29 | 17 | ||||||
Total share-based compensation | $ | 78 | $ | 52 |
The following table presents the share-based compensation expense recognized for stock-based options during the six months ended December 31, 2017 and 2016 (in thousands):
Six Months | Three Months | |||||||||||||||
2017 | 2016 | 2018 | 2017 | |||||||||||||
Cost of product sales | $ | 29 | $ | 44 | $ | 10 | $ | 16 | ||||||||
Research and development expenses | 38 | 15 | 18 | 19 | ||||||||||||
Sales and marketing expenses | 34 | 26 | 22 | 17 | ||||||||||||
General and administrative expenses | 67 | 37 | 43 | 38 | ||||||||||||
Total share-based compensation | $ | 168 | $ | 122 | $ | 93 | $ | 90 |
As of December 31, 2017,September 30, 2018, total unrecognized compensation expense related to stock-based options was approximately $722,000$615,000 and the related weighted-average period over which it is expected to be recognized is approximately 1.271.12 years.
A summary of stock options within the Company’sCompany’s share-based compensation plans as of December 31, 2017 September 30, 2018 was as follows (in thousands except for exercise prices and terms):
Weighted | Weighted | |||||||||||||||||||||||||||||||
Weighted | Average | Weighted | Average | |||||||||||||||||||||||||||||
Number of | Exercise | Contractual | Intrinsic | Number of | Exercise | Contractual | Intrinsic | |||||||||||||||||||||||||
As of December 31, 2017 | Options | Price | Term (Years) | Value | ||||||||||||||||||||||||||||
As of September 30, 2018 | Options | Price | Term (Years) | Value | ||||||||||||||||||||||||||||
Outstanding | 3,295 | $ | .76 | 7.40 | $ | 36 | 3,787 | $ | 0.69 | 7.55 | $ | 128 | ||||||||||||||||||||
Vested and expected to vest | 3,192 | $ | .76 | 7.34 | $ | 36 | 3,779 | $ | 0.68 | 7.55 | $ | 128 | ||||||||||||||||||||
Vested and exercisable | 1,747 | $ | .91 | 5.54 | $ | 36 | 2,082 | $ | 0.82 | 6.15 | $ | 78 |
There were 82,810 and 6,800no stock options exercised, with approximately nil and $3,000 of intrinsic value associated with these exercises during the three months ended December 31,September 30, 2018 and 2017,and 2016, respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.
There were no82,500 and 10,00075,000 option awards granted with a fair value of approximately $0$35,000 and $4,000$33,000 during the three months ended December 31,September 30, 2018 and 2017, and 2016,respectively.
There were 10,000 and no stock option awards which expired during the three months ended December 31,September 30, 2018 and 2017, and 2016,respectively.
There were 16,87538,750 and 47,66959,666 stock option awards forfeited during the three months ended December 31,September 30, 2018 and 2017, and 2016,respectively.
There were 82,810 and 6,800 stock options exercised, with approximately nil and $3,000 of intrinsic value associated with these exercises during the six months ended December 31, 2017 and 2016, respectively. The Company’s current policy is to issue new shares to satisfy stock option exercises.
There were75,000 and 10,000 option awards granted with a fair value of approximately $33,000 and $4,000 during the six months ended December 31, 2017 and 2016, respectively.
There were no and 280,534 stock option awards which expired during the six months ended December 31, 2017 and 2016, respectively.
There were 76,541 and 83,005 stock option awards forfeited during the six months ended December 31, 2017 and 2016, respectively.
8. | Commitments and Contingencies |
Isotope Purchase Agreement
In December 2015, the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cs-131Cesium-131 manufactured by the Institute of Nuclear Materials. The purchase agreement provided the Company with one year’s supply of Cs-131.Cesium-131. The original agreement was due to expire on March 31, 2017, but in December 2016 an addendum was signed extending it until December 31, 2017. On October 23, 2017, the Company, together with The Open Joint Stock Company signed an addendum to the contract to include Cs-131Cesium-131 manufactured at the Research Institute of Atomic Reactors ("SSC RIARRIAR") and extendingextended it until December 31, 2018. On March 19, 2018, an addendum was signed increasing the amount of Cesium-131 to be provided to the Company through December 31, 2018.
Research and Development - Collaborative Arrangement
On March 13, 2017, IsoRay Medical, Inc., a wholly owned subsidiary of the Company (“Medical”), entered into a Collaborative Development Agreement (CDA) with GammaTile,, LLC to further develop a brachytherapy medical device for the treatment of cancerous tumors in the brain and to seek regulatory approval for the new product. As the project manager, Medical will incurincurs all costs in connection with the collaboration project which has beenwill be shared equally by both parties as of November 8, 2016, which is when they informally began the collaboration. The start of the formal collaboration has been extended from December 2017 until March 2018. In accordance with ASC 808 “Collaborative Arrangements”, this activityarrangement is accounted for as a collaborative arrangement and related costs are incurred, shared, and separately stated in connection with a collaborative research and development project. These costs are reported on the financial statements under “Research and development: Collaboration arrangements, net of reimbursement.” The Company collaborated with GammaTile LLC in filing applications to the U.S. Food and Drug Administration (FDA) to clear GammaTile™ for clinical use, and a New Technology Add-on Payment (NTAP) to the Center for Medicare and Medicaid Services (CMS) seeking re-imbursement for the GammaTile™ treatment in the in-patient setting. The application with the FDA is ongoing, however, the NTAP was filed in October 2017.
During the three months ended December 31,September 30, 2018 and 2017,and 2016, costs incurred in connection with the collaboration agreement were $58,000$116,000 and $0,$147,000, respectively.
During the six months ended December 31, 2017 and 2016, costs incurred in connection with the collaboration agreement were $205,000 and $0, respectively.
As of December 31, 2017September 30, 2018 and June 30, 2017, 2018, the Company had outstanding receivables from GammaTile LLC of $15,000$82,000 and $66,000$22,000 respectively. These amounts are included in the Prepaid expenses and other current assets on the consolidated balance sheet.
Derivative Complaint related to Shareholder Value
On September 29, 2016, David M. Kitley, purportedly on behalf of IsoRay, filed a derivative lawsuit in the United States District Court for the District of Minnesota under the case caption Kitley v. IsoRay, Inc., Case No.0:16-cv-03297-DTS. The complaint named as defendants current and former IsoRay directors Dwight Babcock, Thomas LaVoy, Philip J. Vitale and Michael W. McCormick, alleging that they violated their fiduciary duties to IsoRay in connection with a press release allegedly containing false and misleading statements concerning the results from a peer reviewed study of its Cesium-131 isotope seeds for the treatment of non-small cell lung cancers, thereby artificially inflating the price of IsoRay stock. The complaint sought unspecified damages, in an amount not presently determinable, among other forms of relief.
On November 17, 2016, IsoRay moved to dismiss the complaint, arguing that plaintiff was not entitled to pursue his derivative claims due to his failure to serve a pre-suit demand on IsoRay’s board. Rather than respond to the motion to dismiss, plaintiff filed an amended complaint on January 23, 2017. The amended complaint alleged the same derivative claims as the original, and added IsoRay director Alan Hoffmann as a defendant. Plaintiff sought an award of damages and an order directing IsoRay to undertake reforms of its corporate governance and internal procedures. IsoRay moved to dismiss the amended complaint on March 9, 2017. Plaintiff responded on April 20, 2017, and IsoRay replied on May 17, 2017. The court heard oral argument on the motion on August 22, 2017, and took the matter under advisement at that time. On October 19, 2017, the court granted IsoRay’s motion to dismiss. The matter is now resolved.
Media Advertising Agreement
On October 3, 2017, the Company entered into a Media Advertising Agreement with Al & J Media Inc., a corporation incorporated in the State of New York (the “Consultant”).
Pursuant to the agreement, the Consultant was to introduce the Company to potential sources of media, marketing agreements, and/or strategic alliances, including but not limited to radio and television media advertising, various media publications, and Internet podcasts. The Consultant did not promote the Company as part of the agreement; it acted only as a media agent for advertising.
OnDecember 29, 2017, the Company notified the Consultant of its decision to terminate the agreement between the parties because the Consultant’s services were no longer needed.
As compensation for the services provided prior to termination, the Company paid the Consultant $60,000 and issued the Consultant 250,000 warrants upon execution of the agreement, which vested immediately, entitling the Consultant to purchase shares of Company common stock, exercisable on or before October 3, 2020, at an exercise price of $0.54 per share.
9. | Fair Value Measurements |
The following table sets forth the Company’sCompany’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands):
Fair Value at December 31, 2017 | ||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | |||||||||||||
Cash and cash equivalents | $ | 2,951 | $ | 2,951 | $ | - | $ | - |
Fair Value at September 30, 2018 | ||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | |||||||||||||
Cash and cash equivalents | $ | 2,193 | $ | 2,193 | $ | - | $ | - |
Fair Value at June 30, 2017 | ||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | |||||||||||||
Cash and cash equivalents | $ | 5,932 | $ | 5,932 | $ | - | $ | - |
Fair Value at June 30, 2018 | ||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | |||||||||||||
Cash and cash equivalents | $ | 2,600 | $ | 2,600 | $ | - | $ | - |
The Company’sCompany’s cash and cash equivalent instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
| Related Party |
DuringThere were no related party transactions during the quarter ended June 30, 2016, the Company engaged GO Intellectual Capital, LLC (GO) for marketing services in support of the Company’s rebranding effort. Michael McCormick, a member of the Company Board of Directors, is a 1/3 owner of GO. A statement of work was developed defining the scope of the effort and the deliverables to the Company including a new logo with brand messaging and communication tools including a website, sales presentation tools and a public relations strategy. For the sixthree months ended December 31, 2016, the Company paid approximately $20,000 to GO for its performance of work related to the agreed upon statement of work. No such services were provided in the six months ended December 31,September 30, 2018 and 2017.
| Concentrations of Credit and Other Risks |
One group of customers, facilities or physician practices hasaccounts for revenues that aggregate to greater than 10% of total Company product sales:
| ||||||||
|
| |||||||
|
|
| ||||||
|
1 –sales. This group of facilities individually each comprise lessdo not aggregate to more than 10% of total Company product sales. They are serviced by the same physician group, one of whom is our Medical Director.Director:
Three months ended | ||||||||
September 30, | September 30, | |||||||
Facility | 2018 | 2017 | ||||||
El Camino Hospital of Los Gatos, & other facilities | 25.18% | 25.98% |
The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.necessary.
|
|
WarrantsOn July 11, 2018, the Company completed the closing of a registered direct offering with several institutional and accredited investors (each an “Investor”) for the sale of a total of 11,000,000 shares of common stock of the Company (“Shares”) at a price per share of $0.75, for aggregate gross proceeds to the Company of $8.25 million. Cash expenses relating to this offering were approximately $0.75 million.
As part
In a concurrent private placement, the Company sold to each Investor, at no additional consideration, unregistered warrants to purchase up to the number of shares of common stock of the compensation for the services performed by Al & J Media Inc.Company equal to 50% of such Investor’s Shares or a total of 5,500,000 shares, with an exercise price of $0.75 per share, exercisable from January 11, 2019 until January 11, 2024 (the "Consultant"“Investor Warrants”) pursuant. The Company also issued warrants to the Media Advertising Agreement discussed on page 8, the Consultant received 250,000 warrants upon executionpurchase up to 330,000 shares of common stock of the agreement, which vested immediately, entitling the Consultant to purchase shares of Company, common stock, exercisable on or before October 3, 2020, at an exercise price of $0.54 each. These warrants,$0.9375, to representatives of H.C. Wainwright & Co., LLC (“Wainwright”), the placement agent for the registered direct offering, as part of its compensation (the “Placement Agent Warrants” and together with the Investor Warrants, the “Warrants”).
The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000 shares relating to this offering. We will receive gross proceeds from this offering solely to the extent any Warrants are exercised for cash.
13. | Contracts with Customers |
We have adopted ASC 606, Revenue from Contracts with Customers effective July 1, 2018 using the Black-Scholesmodified retrospective method applied to those contracts which were not substantially completed as of July 1, 2018. These standards provide guidance on recognizing revenue, including a five-step model resultedto determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in approximately $72,000an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenues for fiscal year 2019 are reported under ASC 606, while prior period amounts are not adjusted and continue to be reported under ASC 605, Revenue Recognition.
We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products that we offer. However, these agreements do not obligate us to provide goods to the customer and there is no consideration promised to us at the onset of additional share based compensation duringthese arrangements. For customers without separate agreements, we have a standard list price established for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the delivery of the requested product(s) in appropriate quantities and to the location specified in the customer’s e-mail/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are not affected by contingent events that could impact the transaction price. We do not offer price concessions and do not accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do not have any material performance obligations where we are acting as an agent for another entity.
Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.
Sources of Revenue
We have identified the following revenues disaggregated by revenue source:
1. | Domestic Physicians – direct sales of products. | |
2. | International – direct sales of products. |
For the three months ended December 31,2017. On December 29,September 30, 2018 and 2017 the Company notifiedhad revenue from both sources. International revenues in both periods was immaterial.
Contract Balances
We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the Consultantshort duration of its decisiontime between order acceptance and delivery of the related product, we have determined that the balance related to terminatethese obligations is generally immaterial at any point in time. We monitor the Media Advertising Agreement.value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.
The key assumptionsWarranty
Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.
Returns
Generally, we allow returns if not implanted and we are notified within a few weeks after satisfying our performance obligations of a return.
Significant Judgments in the Application of the Guidance in ASC 606
There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.
Commissions and Contract Costs
We pay and expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.
Practical Expedients
Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists.
Shipping and Handling Charges
Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of products.
Taxes Collected from Customers
As our products are used in the Black-Scholes valuation modelanother service and are exempt, to calculatethis point we have not collected taxes. If we were to collect taxes they would be on the fair value of the warrants are as follows:transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.
October 3, | ||||
2017 | ||||
Grant date fair value | $ | 0.2874 | ||
Options issued | 250,000 | |||
Exercise price | $ | 0.54 | ||
Expected term (in years) | 3 | |||
Risk-free rate | 1.62 | % | ||
Volatility | 81.66 | % |
Effective Date and Transition Disclosures
The following table summarizes all warrants outstanding asAdoption of the beginning of the fiscal year, all activitynew standards related to warrants issued, cancelled, exercised or expired during the periodrevenue recognition did not have a material impact on our consolidated financial statements, and weighted average prices by category.is not expected to have a material impact in future periods.
Weighted average | ||||||||
Warrants | exercise price | |||||||
Outstanding as of June 30, 2017 | - | $ | - | |||||
Warrants issued | 250,000 | $ | 0.54 | |||||
Outstanding as of December 31, 2017 | 250,000 | $ | 0.54 |
The following table summarizes additional information about the Company’s common warrants outstanding as of December 31, 2017:
Number of Warrants | Exercise Price¹ | Expiration Date | ||||
250,000 | $ | 0.54 | October 2020 |
| Subsequent Events |
ManufacturingOn October 19, 2018, the Company filed a Form S-1 registration statement for the registration of 5,830,000 shares of common stock to be received by the investors and Supply Agreement between Medical and GT Medical Technologiesrepresentatives of Wainwright on exercise of Warrants issued in connection with a registered direct offering completed on July 11, 2018 whereby the Company received gross proceeds of $8,250,000. The Company may receive up to $4,434,375 in gross proceeds solely to the extent the Warrants are exercised for cash, but they can't be exercised until January 11, 2019.
On January 3,November 7, 2018, Medical and GT Medical Technologies, Inc. (“GT Tech”) the Company entered into a Manufacturingan Amendment and SupplyTermination of Share Rights Agreement (the “Supply Agreement”“Amendment”).
Pursuant to with Computershare Trust Company, N.A. (the “Rights Agent”), which amended that certain Share Rights Agreement (the “Rights Agreement”), dated as of February 1, 2007, as amended, by and between the Supply Agreement, Medical will manufactureCompany and supply a brachytherapy product that incorporates Cesium-131 seeds within customizable carriers configured as squares or rectangles for the treatment of brain tumors (the “GammaTile™ Product”), developed pursuant toRights Agent. The Amendment accelerates the Collaborative Development Agreement. Once regulatory clearance from the U.S. Food and Drug Administration permitting marketingexpiration date of the GammaTile™ ProductRights Agreement to November 7, 2018, such that, as of 5:00 p.m. Richland, Washington time on November 7, 2018, the Series C Junior Participating Preferred Shares purchase rights expired and are no longer outstanding and the Rights Agreement terminated and is received (the “510(k) Clearance”), Medical will exclusively manufacture and supply the GammaTile™ Product for end users designated by GT Tech. Additionally, Medical will supply looseof no further force or braided Cesium-131 seeds for brachytherapy brain cancer treatment to GT Tech on a non-exclusive basis. The prices for the GammaTile™ Product and Cesium-131 seeds are set forth on Exhibit B of the Supply Agreement, subject to periodic adjustment, with an initial price per seed of between $130 and $150 depending on quantity ordered. As part of the Supply Agreement, Medical has agreed to transfer the 510(k) Clearance to GT Tech within 30 days of receipt. The term of the Supply Agreement is 10 years.effect.
ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Caution Regarding Forward-Looking Information
In addition to historical information, this Form 10-Q10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA.
All statements contained in this Form 10-Q,10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A - Risk Factors beginning on page 1817 below that may cause actual results to differ materially.
Consequently, all of the forward-looking statements made in this Form 10-Q10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company’s views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Critical Accounting Policies and Estimates
The discussion and analysis of the Company’sCompany’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company’s annual report on Form 10-K as filed with the SEC on September 28, 201726, 2018 are those that depend most heavily on these judgments and estimates. As of December 31, 2017September 30, 2018 there had been no material changes to any of the critical accounting policies contained therein.
Overview
IsoRay Inc. is a brachytherapy device manufacturer with FDA clearance and CE marking for a single medical device that can be delivered to the physician in multiple configurations as prescribedprescribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Cesium-131 brachytherapy seed.
The brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows.
The Company has distribution agreements outside of the United States through its subsidiary IsoRay International LLC. These distributors are responsible for obtaining regulatory clearance to sell the Company’sCompany’s products in their territories, with the support of the Company. As of the date of this Report, the Company had distributors in Italy, Switzerland, and the Russian Federation.Federation, with $18,000 of reported revenues in the quarter ended September 30, 2018.
Results of Operations
Three months ended September 30, December 312018 ,and 2017 and 2016 (in thousands):
Three months ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2017 - 2016 | ||||||||||||||||||
Amount | % (a) | Amount | % (a) | % Change | ||||||||||||||||
Product sales, net | $ | 1,536 | 100 | $ | 1,028 | 100 | 49 | |||||||||||||
Cost of product sales | 1,005 | 65 | 1,029 | 100 | (2 | ) | ||||||||||||||
Gross profit / (loss) | 531 | 35 | (1 | ) | - | 53,200 | ||||||||||||||
Operating expenses: | ||||||||||||||||||||
Research and development expenses - proprietary | 311 | 20 | 150 | 15 | 107 | |||||||||||||||
Research and development expenses – collaboration agreement, net of reimbursement | 29 | 2 | - | - | 100 | |||||||||||||||
Sales and marketing expenses | 674 | 44 | 496 | 48 | 35 | |||||||||||||||
General and administrative expenses | 985 | 64 | 880 | 86 | 12 | |||||||||||||||
Change in estimate of ARO | - | - | (48 | ) | (5 | ) | (100 | ) | ||||||||||||
Total operating expenses | 1,999 | 130 | 1,478 | 144 | 35 | |||||||||||||||
Operating loss | (1,468 | ) | (95 | ) | (1,479 | ) | (144 | ) | 1 |
|
|
Six months ended December 31, 2017 and 2016 (in thousands):
Six months ended December 31, | Three months ended September 30, | |||||||||||||||||||||||||||||||||||||||
2017 | 2016 | 2017 - 2016 | 2018 | 2017 | 2018 - 2017 | |||||||||||||||||||||||||||||||||||
Amount | % (a) | Amount | % (a) | % Change | Amount | % (a) | Amount | % (a) | % Change | |||||||||||||||||||||||||||||||
Product sales, net | $ | 2,747 | 100 | $ | 2,109 | 100 | 30 | $ | 1,562 | 100 | $ | 1,211 | 100 | 29 | ||||||||||||||||||||||||||
Cost of product sales | 1,951 | 71 | 2,062 | 98 | (5 | ) | 1,038 | 66 | 946 | 78 | 10 | |||||||||||||||||||||||||||||
Gross profit / (loss) | 796 | 29 | 47 | 2 | 1,594 | |||||||||||||||||||||||||||||||||||
Gross profit | 524 | 34 | 265 | 22 | 98 | |||||||||||||||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||||||||||||
Research and development expenses - proprietary | 597 | 22 | 322 | 15 | 85 | 394 | 25 | 287 | 24 | 37 | ||||||||||||||||||||||||||||||
Research and development expenses – collaboration agreement, net of reimbursement | 104 | 4 | 26 | 2 | 75 | 6 | (65 | ) | ||||||||||||||||||||||||||||||||
Sales and marketing expenses | 1,288 | 47 | 1,020 | 48 | 26 | 649 | 42 | 614 | 51 | 6 | ||||||||||||||||||||||||||||||
General and administrative expenses | 1,827 | 67 | 1,807 | 86 | (1 | ) | 973 | 62 | 841 | 69 | 16 | |||||||||||||||||||||||||||||
Change in estimate of ARO | - | - | (48 | ) | (2 | ) | (100 | ) | ||||||||||||||||||||||||||||||||
Total operating expenses | 3,816 | 140 | 3,101 | 147 | 23 | 2,042 | 131 | 1,817 | 150 | 12 | ||||||||||||||||||||||||||||||
Operating loss | (3,020 | ) | (111 | ) | (3,054 | ) | (145 | ) | 1 | (1,518 | ) | (97 | ) | (1,552 | ) | (128 | ) | (2 | ) |
(a) | Expressed as a percentage of product sales, net |
Product Sales
Changes in sales personnel and implementation of a revitalized sales and marketing strategy in the second quarter of fiscal 2017 has resultedcontinued to result in ongoing positive sales growth in the secondfirst quarter of fiscal 20182019 when compared to prior year secondfirst quarter. Ongoing training and support of new sales personnel has led to not only new accounts but also reconnecting with and receiving orders from prior accounts.
Three months ended September 30, 2018 and 2017 (in thousands)
Three months ended September 30, | ||||||||||||||||||||
2018 | 2017 | 2018 - 2017 | ||||||||||||||||||
Amount | % (a) | Amount | % (a) | % Change | ||||||||||||||||
Prostate brachytherapy | $ | 1,376 | 88 | $ | 1,084 | 89 | 27 | |||||||||||||
Other brachytherapy | 186 | 12 | 127 | 11 | 46 | |||||||||||||||
Product sales, net | 1,562 | 100 | 1,211 | 100 | 29 |
(a) Expressed as a percentage of product sales, net
Three months ended December 31, 2017 and 2016 (in thousands)
Three months ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2017 - 2016 | ||||||||||||||||||
Amount | % (a) | Amount | % (a) | % Change | ||||||||||||||||
Prostate brachytherapy | $ | 1,315 | 86 | $ | 889 | 86 | 48 | |||||||||||||
Other brachytherapy | 221 | 14 | 139 | 14 | 59 | |||||||||||||||
Product sales, net | 1,536 | 100 | 1,028 | 100 | 49 |
|
|
Six months ended December 31, 2017 and 2016 (in thousands)
Six months ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2017 - 2016 | ||||||||||||||||||
Amount | % (a) | Amount | % (a) | % Change | ||||||||||||||||
Prostate brachytherapy | $ | 2,399 | 87 | $ | 1,855 | 88 | 29 | |||||||||||||
Other brachytherapy | 348 | 13 | 254 | 12 | 37 | |||||||||||||||
Product sales, net | 2,747 | 100 | 2,109 | 100 | 30 |
|
|
Prostate Brachytherapy
Prostate brachytherapy sales were impacted by changes in sales account managers and by the schedules of some key accounts in the first quarter of the fiscal year. During the quarter ended December 31, 2017,September 30, 2018, the Company had a full sales team in place contributing to the increase in sales. Also, website improvements and significant investments in product support literature, social media and public relations are increasing the awareness of the Company in the prostate brachytherapy treatment markets providing the Company opportunities to develop new customers and reconnect with past customers.
Management believes growth in prostate brachytherapy revenues will be the result of physicians, payers, and patients increasingly considering overall brachytherapy treatmenttreatment advantages including costs, better treatment outcomes and improvement in the quality of life for patients, when compared with non-brachytherapy treatments.
During the quarter ended December 31, 2017, approximately $35,000 of reported revenues originated from the international market.
Management believes increased pressure to deliver effective healthcare in both terms of outcomeoutcome and cost drove treatment options, and accordingly drove the Company’s prostate revenues, in the quarter ended December 31, 2017.September 30, 2018.
Other BrachythBrachytherapyerapy
Other brachytherapy includes, but is not limited to, brain, lung, head/neck, and gynecological treatments.treatments. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable.
These other brachytherapy treatments continue to be subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians.physicians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from quarter to quarter. This volatility resulted in the increase from the prior year.
Cost of product sales
Cost of product sales consists primarily of the costs of manufacturing and distributing the Company’s products.
Contributing to the threequarters ended September 30, 2018 and six2017 comparison were increased isotope and other direct materials purchases as well as increased labor to meet production demand due to improved sales. Also contributing to the increase are higher depreciation costs due to completed automation projects placed into service.
Gross Profit
Contributing to the three months ended December 31,September 30, 2018 and 2017 and 2016gross profit comparison were decreases attributed to cost savings initiatives that resulted in lower procurement costs of goods and services. Some costs shifted in the three and six months ended December 31, 2017 to research and development from cost of productincreased sales as employees performed research and development work. Also, reduced staffing costs were realized with decreased head count. These decreases were partially offset by increased supply of isotope from MURR which increased total cost of product sales but resulted in lower supply cost per curie of Cesium-131.materials and labor costs to meet production demand.
ResearchResearch and development
Research and development – proprietary
Proprietary research and development consists primarily of employee and third-partythird party costs related to research and development activities.
Contributing to the three monthsquarters ended December 31,September 30, 2018 and 2017 and 2016 proprietary research and development comparison were increases associated with participation in new protocols, device development activities, as well as a reallocation of employee costs from cost of product sales as those employees performed work on research and development projects.
Contributing to the six months ended December 31, 2017 and 2016 proprietary research and development comparison were increases associated with participation in new protocols, device development activities, as well as a reallocation of employee costs from cost of product sales as those employees performed work on research and development projects.activities. These increases were partially offset by decreased legal fees.fees and travel.
Research and development – collaborative arrangement
Collaboration arrangement related costs are incurred, shared, and separately stated in connection with a collaborative research and development project (see note 8 of the financial statements contained in this filing).
Contributing to the quarters ended September 30, 2018 and 2017 comparison were decreased costs due to the fact that payments being made pursuant to the collaborative arrangement with GammaTile, LLC.
DuringLLC were no longer necessary at the three months ended December 31, 2017 and 2016, costs incurredsame level, as the collaborative arrangement primarily related to work involved in connection with the collaboration agreement were $58,000 and $0, respectively.
During the six months ended December 31, 2017 and 2016, costs incurred in connection with the collaboration agreement were $205,000 and $0, respectively.obtaining 510(k) clearance, which has now been obtained.
Sales and marketing expenses
Sales and marketing expenses consist primarily of the costs related to the internal and external activities of the Company’sCompany’s sales, marketing and customer service functions of the Company. As the Company increasingly focuses on improving sales, the cost associated with marketing and greateradditional staffing continues to increase.
Staffing differences are a major factor in the cost comparison for the three months ended December 31, 2017 and 2016 as open positions in the quarter ended December 31, 2016 were filled in periods prior to the quarter ended December 31, 2017 with increased salaries and increased travel costs. Due to increased sales, there were also increases in commission and bonus expense.
Contributing to the six monthsquarters ended December 31,September 30, 2018 and 2017 and 2016 comparison were increased advertising and public relationswas a decrease in travel costs as part of the revitalized marketing plan.a tradeshow that occurred in September 2017 did not occur until October 2018. Staffing differences are a major factor in the cost comparison as open positionspositions in six monthsthe quarter ended December 31, 2016September 30, 2017 were filled in periods prior to the quarter ended December 31, 2017 with increased salaries.September 30, 2018, thereby increasing personnel costs.
GeneralGeneral and administrative expenses
General and administrative expenses consist primarilyprimarily of the costs related to the executive, human resources/training quality assurance/regulatory affairs, finance, and information technology functions of the Company.
Contributing to the three monthsquarters ended December 31,September 30, 2018 and 2017 and 2016 comparison were cost increases associated with share-based compensation, bonus expense, public company related expense, and state tax expense. These cost increases were partially offset in the three months ended December 31, 2017 by decreases to payroll as a result of the re-organization of the finance department with reduced head count, decreased legal expenses, and decreased employee hiring costs.
Contributing to the six months ended December 31, 2017 and 2016 comparison were cost decreases from the prior year. Those include decreases to payroll as a result of the re-organization of the finance department with reduced head count, decreased legal expenses, auditincrease in headcount, salary increases implemented in July 2018, and bank fees, and seminars, conference, and training expenses. These cost decreases were partially offset in the six months ended December 31, 2017 by increases associated with share-basedincentive compensation bonus expense, state taxes, and employment hiring expenses related to the hiring of the Controller.increase in revenue.
Liquidity and capital resources
The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the quartersquarters ended December 31,September 30, 2018 and 2017, and 2016, the Company used existing cash reserves to fund its operations and capital expenditures (in thousands except current ratio):
Six months | ||||||||
ended December 31, | ||||||||
2017 | 2016 | |||||||
Net cash used by operating activities | $ | (3,184 | ) | $ | (3,014 | ) | ||
Net cash provided by investing activities | 164 | (448 | ) | |||||
Net cash provided by financing activities | 39 | (9 | ) | |||||
Net decreases in cash and cash equivalents | $ | (2,981 | ) | $ | (3,471 | ) |
As of | Three months | |||||||||||||||
ended September 30, | ||||||||||||||||
2018 | 2017 | |||||||||||||||
Net cash used by operating activities | $ | (1,612 | ) | $ | (1,661 | ) | ||||||||||
Net cash (used) by investing activities | (6,289 | ) | (315 | ) | ||||||||||||
Net cash provided by financing activities | 7,494 | - | ||||||||||||||
Net (decrease) in cash and cash equivalents | $ | (407 | ) | $ | (1,976 | ) | ||||||||||
December 31, 2017 | June 30, 2017 | |||||||||||||||
Working capital | $ | 6,486 | $ | 9,185 | $ | 9,631 | $ | 7,799 | ||||||||
Current ratio | 7.96 | 9.30 | 6.88 | 8.31 |
Cash flows from operating activities
Net cash used by operating activities in the sixthree months ended December 31, 2017September 30, 2018 was primarily due to a net loss of approximately $3.01$1.51 million, net of approximately $317,000$140,000 in adjustments for non-cash activity such as depreciation and amortization expense, ARO accretion, and share-based compensation. Changes in operating assets and liabilities used approximately $491,000$249,000 to fund operating activities; Increase in accounts receivableincreases to prepaid expenses and inventory, along with decreases into accounts payable and accrued expenses and accrued payroll and related taxes were partially offset by decreases in accounts receivable resulting from improved collections as well as an increase in accrued payroll and related taxes.protocol expense.
Cash flows from investing activities
Investing activities consisted of transactions related to the purchase of fixed assets, including automation of production processes and advance planning and design work on the Company’s new production facility, as well as the purchase and subsequent maturity of certificates of deposit. Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest maturing certificates of deposit in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.
Cash flows from financingFinancing activities
Financing activities in the six monthsquarter ended December 31, 2017 included payment of preferred dividends and proceeds of salesSeptember 30, 2018 were due to the sale of common stock through option exercises.a registered direct offering (see note 12 to the financial statements). There were no financing activities in the quarter ended September 30, 2017.
Projected 20182019 Liquidityliquidity and Capital Resourcescapital resources
Operating activities
Management forecasts that current cash and cash equivalents along with certificates of deposit will be sufficient to meet projected operating cash needs for the remainder of fiscal 2018 and into the first half of fiscal 2019. Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy of renewed emphasis on driving the consumer to the prostate market, meets or exceeds its annual growth targets of twentytwenty-five percent increase in revenue in fiscal 20182019 and this annual growth continues, the Company anticipates reaching cashflow break-even in three to five years. Although theThe Company did not reachexceeded that target of twentytwenty-five percent increased revenue in the first quarter of fiscal 2018, that target was surpassed in the second quarter and the Company is continuing to project revenue growth in fiscal 2018 of at least twenty percent over fiscal 2017.2019. There is no assurance that targeted sales growth will materializecontinue over the next three to five years. However, management is encouraged by the results for the six monthsquarter ended December 31, 2017September 30, 2018 and withby the depth and experience of its restructured sales team.
Capital expenditures
Management has completed the design of a future production and administration facility. If financing is obtained andand the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility.
Management is reviewing and implementing changes in all aspects of production operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive product sales.
During the six monthsquarter ended December 31, 2017,September 30, 2018, the Company invested approximately $112,000$50,000 in the automation of thirteen production processes, threefour of which have been received, tested and evaluated, and were placed in service in the six months. One additional machine has been received and is currently being tested. Beginning in fiscal 2017 and continuing through December 31, 2017,into service. Through September 30, 2018, the Company has invested approximately $412,000$430,000 in these automation projects, and management is expecting to invest approximately $400,000$215,000 more over the next 189 months on the remaining projects. This investment is designed to allow the Company to significantly increase the output of Cs-131 brachytherapy seeds while allowing the Company to decrease the labor costs related to seed production and also improving the overall safety of our operations.
Financing activities
There was no material change in the use of proceeds from our public offering as described in our final prospectus supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through December 31, 2017,September 30, 2018, the Company had used the net proceeds raised through the March 2014 offering as described in the public offering. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.
On August 25, 2015, the Company filed a registration statement on Form S-3 to register securities up to $20 million in value for future issuance in our capital raising activities. The registration statement became effectiveeffective on November 19,23, 2015, and the SEC file number assigned to the registration statement is 333-206559.
On July 11, 2018, the Company sold 11,000,000 shares of its common stock at a price of $0.75 per share, for aggregate gross proceeds of $8.25 million, pursuant to the registration statement on Form S-3 that became effective on November 23, 2015. The Company has not yet used any proceeds from this offering. Additionally, the Company issued to the purchasers unregistered warrants to purchase up to 5,500,000 shares of common stock. The warrants have an exercise price of $0.75 per share common stock, are exercisable commencing six months following the issuance date, and expire five and one-half years from the issuance date. If exercised for cash, future exercises of these warrants will provide additional capital to the Company. As a result of this recent capital raise, the Company does not anticipate the need to finance its operations for the next fiscal year from additional capital raises.
The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders. Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.
The Company’s common stock is currently listed on the NYSE American stock exchange, which will consider delisting a company’s securities if, among other things, a company fails to maintain minimum stockholder's equity. With the Company’s existing cash reserves, we believe we will not be able to maintain our listing on the NYSE American unless we raise capital in the next three to six months assuming we maintain our projected budgeted expensesOther commitments and contemplated level of revenues.
Other Commitments and Contingenciescontingencies
The Company presented its other commitmentscommitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017.2018. There have been no material changes outside of the ordinary course of business in those obligations during the quarter ended December 31, 2017September 30, 2018 other than those previously disclosed in Notesnote 8 and 13of to the interim financial statements contained in this Form 10-Q.filing.
Off-Balance Sheet ArrangementsOff-balance sheet arrangements
The Company has no off-balance sheet arrangements.
Critical Accounting Policiesaccounting policies and Estimatesestimates
TheThe discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).GAAP. The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.
During the quarter ended December 31, 2017,September 30, 2018, there have been no changes to the critical accounting policies and estimates as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2017.2018.
ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes to the disclosure in the “Quantitative“Quantitative and Qualitative Disclosures about Market Risk Factors” section of our Annual Reportannual report on Form 10-K for the year ended June 30, 2017.2018, which is incorporated herein by reference.
ITEM 4 – CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term isis defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of December 31, 2017.September 30, 2018. Based on that evaluation, our principal executive officer and our principal financial officer concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met.
Changes in Internal Control over Financial Reporting
There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act)Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
The Company may, in the ordinary course of business, be subjectNothing to various legal proceedings. Some legal proceedings are discussed in footnote 8 of Notes to Unaudited Consolidated Financial Statements contained in this filing. We refer you to that footnote for important information concerning those legal proceedings, including the basis for such actions and, where known, the relief sought.disclose.
Derivative Complaint related to Shareholder Value
On September 29, 2016, David M. Kitley, purportedly on behalf of IsoRay, filed a derivative lawsuit in the United States District Court for the District of Minnesota under the case caption Kitley v. IsoRay, Inc., Case No. 0:16-cv-03297-DTS. The complaint named as defendants current and former IsoRay directors Dwight Babcock, Thomas LaVoy, Philip J. Vitale and Michael W. McCormick, alleging that they violated their fiduciary duties to IsoRay in connection with a press release allegedly containing false and misleading statements concerning the results from a peer reviewed study of its Cesium-131 isotope seeds for the treatment of non-small cell lung cancers, thereby artificially inflating the price of IsoRay stock. The complaint sought unspecified damages, in an amount not presently determinable, among other forms of relief.
On November 17, 2016, IsoRay moved to dismiss the complaint, arguing that plaintiff was not entitled to pursue his derivative claims due to his failure to serve a pre-suit demand on IsoRay’s board. Rather than respond to the motion to dismiss, plaintiff filed an amended complaint on January 23, 2017. The amended complaint alleged the same derivative claims as the original, and added IsoRay director Alan Hoffmann as a defendant. Plaintiff sought an award of damages and an order directing IsoRay to undertake reforms of its corporate governance and internal procedures. IsoRay moved to dismiss the amended complaint on March 9, 2017. Plaintiff responded on April 20, 2017, and IsoRay replied on May 17, 2017. The court heard oral argument on the motion on August 22, 2017, and took the matter under advisement at that time. On October 19, 2017, the court granted IsoRay’s motion to dismiss. The matter is now resolved.
A description of the risk factors associated with our business is included under “Risk“Risk Factors” contained in Part I, Item 1A of our annual report on Form 10-K for the year ended June 30, 2017,2018, and is incorporated herein by reference. There have been no material changes in our risk factors since such filing, except for the following:
We Rely Heavily Onon Five Customers
For the sixthree months ended December 31, 2017September 30, 2018 approximately 46%48% of the Company’s revenues were dependent on five customers with approximately 24%25% being generated by one customer.group of customers. The loss of any of these customers would have a material adverse effect on the Company’s revenues whichthat may not be replaced by other customers particularly as these customers are in the prostate sector which is facing substantial competition from other treatments.
We Will Need Additional Capital In The Future To Maintain Our NYSE American Listing And For Acquisitions And Expansion Into Other Markets.
Our common stock is currently listed on the NYSE American stock exchange which will consider delisting a company’s securities if, among other things, a company fails to maintain minimum stockholder's equity. With our existing cash reserves we believe we will not be able to maintain our listing on the NYSE American unless we raise capital in the next three to six months assuming we maintain our projected budgeted expenses and contemplated level of revenues. In the event that our common stock is delisted from the NYSE American, trading, if any, in the common stock would be conducted in the over-the-counter market. As a result, our shareholders would likely find it more difficult to dispose of, or to obtain accurate quotations as to the market value of, our common stock. We may also need to raise capital for strategic acquisitions or expansion into other markets and there is no assurance management will not pursue this additional capital if available.
ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.On July 11, 2018, the Company completed the closing of a registered direct offering with several institutional and accredited investors (each an “Investor”) for the sale of a total of 11,000,000 shares of common stock of the Company (“Shares”) at a price per share of $0.75, for aggregate gross proceeds to the Company of $8.25 million.
In a concurrent private placement, the Company sold to each Investor, at no additional consideration, unregistered warrants to purchase up to the number of shares of common stock of the Company equal to 50% of such Investor’s Shares or a total of 5,500,000 shares, with an exercise price of $0.75 per share, exercisable from January 11, 2019 until January 11, 2024 (the “Investor Warrants”). The Company also issued warrants to purchase up to 330,000 shares of common stock of the Company, at an exercise price of $0.9375, to representatives of Wainwright, the placement agent for the registered direct offering, as part of its compensation (the “Placement Agent Warrants” and together with the Investor Warrants, the “Warrants”).
The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000 shares. The offer and sale of the Warrants was made without registration in reliance on the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 promulgated thereunder. We will receive gross proceeds from this offering solely to the extent any Warrants are exercised for cash.
The Company has not yet used any proceeds from our sale of 11,000,000 shares of common stock on July 11, 2018.
Although we have identified some of the potential uses of the proceeds from this offering, we have and reserve broad discretion in the application of these proceeds. Accordingly, we reserve the right to use these proceeds for different purposes or uses which we have not listed above, particularly if there is a change in demand for certain applications of our Cesium-131 and other products which may require increased investment in protocols and research studies and the hiring of additional sales staff
ITEM 3 – DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4 - MINE SAFETY DISCLOSURES
Not applicable.
None
31.1* |
| Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer | |
|
|
| |
31.2* |
| Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer | |
|
|
| |
32** |
| ||
|
|
| |
101.INS* |
| XBRL Instance Document | |
|
|
| |
101.SCH* |
| XBRL Taxonomy Extension Schema Document | |
|
|
| |
101.CAL* |
| XBRL Taxonomy Extension Calculation Linkbase Document | |
|
|
| |
101.DEF* |
| XBRL Taxonomy Extension Definition Linkbase Document
| |
101.LAB* |
| XBRL Taxonomy Extension Label Linkbase Document | |
|
|
| |
101.PRE* |
| XBRL Taxonomy Extension Presentation Linkbase Document |
* Filed herewith.herewith
** Furnished herewith
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: |
|
|
|
| ISORAY, INC., a Minnesota corporation |
|
|
|
|
|
|
|
| Lori A. Woods |
Interim Chief Executive Officer | ||
|
|
|
|
| |
|
|
|
| /s/ Mark J. Austin | |
| Mark J. Austin | |
|
| Controller |
20
19